CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Multiply Labs›
Analysis
Multiply Labs logo

Multiply Labs

Multiply Labs: Robotic systems for scalable, cost-effective pharma manufacturing.

San Francisco, CA, US🇺🇸
Founded
2016
Accelerator
NVIDIA Inception logoNVIDIA InceptionMember
Accelerator
Y Combinator logoY CombinatorS16
Loading
Overview
Analysis
Compare
Fundraising
Employees
News
Library

Contents

  1. 01Competitive Strengths
  2. 02Executive Summary
  3. 03Products & Services
  1. 01Competitive Strengths
  2. 02Executive Summary
  3. 03Products & Services

Competitive Advantages

Multiply Labs automates the instruments and protocols a pharmaceutical company already uses, so production continues on site without transferring the process to an outside facility. Its no-code process tools let the therapy developer own and adjust the manufacturing sequence, which can reduce revalidation work and keep intellectual control with the customer.

A peer-reviewed study with UC San Francisco found robotic cell expansion matched manual performance while lowering costs, and the company reports deployments with global pharmaceutical organizations. Robots run continuously in sterile conditions without breathing or touching surfaces they should not, improving repeatability and lowering contamination risk.

Source: businesswire.com

Memo

Multiply Labs presents a 65-person team of roboticists, scientists, and engineers based in San Francisco, led by co-founders Fred Parietti as chief executive and Alice Melocchi as chief scientific officer. The roster spans robotics software and hardware, systems integration, quality, product management, and field engineering, with advisors including cell therapy researchers.

Public materials position the company as a robotics supplier to pharmaceutical manufacturers rather than a therapy developer, with named collaborators across the cell therapy industry. The team page emphasizes building automation that expands access to advanced treatments manufactured at scale.

Source: multiplylabs.com

Product Overview

The Robotic Cluster is a modular manufacturing cell that packs four robotic arms and up to 24 instrument towers into under 600 square feet. Each cluster works with the good manufacturing practice instruments a therapy developer already uses, automating more than 50 unit operations such as liquid handling, cell counting, centrifugation, and incubator loading inside a closed sterile environment.

Depending on process length and therapy type, one cluster can produce roughly 2,000 to more than 10,000 doses per year. A no-code process builder lets scientists sequence unit operations visually, while the software logs every step and sensor reading into electronic records for quality review.

Source: multiplylabs.com